Reynolds, Edwardo G. M. http://orcid.org/0000-0002-5148-1479
Lopdell, Thomas
Wang, Yu
Tiplady, Kathryn M.
Harland, Chad S.
Johnson, Thomas J. J.
Neeley, Catherine
Carnie, Katie
Sherlock, Richard G.
Couldrey, Christine
Davis, Stephen R.
Harris, Bevin L.
Spelman, Richard J.
Garrick, Dorian J.
Littlejohn, Mathew D.
Funding for this research was provided by:
Ministry of Business, Innovation and Employment (LICX1802)
Article History
Received: 30 August 2021
Accepted: 21 December 2021
First Online: 24 January 2022
Declarations
:
: All animal experiments were conducted in strict accordance with the rules and guidelines outlined in the New Zealand Animal Welfare Act 1999. The majority of genotype and phenotype data were generated as part of routine commercial activities outside the scope of that requiring formal committee assessment (as defined by the above guidelines).
: Not applicable.
: TL, YW, KT, CSH, TJJJ, CN, KC, RGS, CC, SRD, BLH, RJS, MDL are employees of Livestock Improvement Corporation (LIC; Hamilton, New Zealand), a commercial provider of bovine germplasm. Livestock Improvement Corporation is the applicant for several patent applications related to some of the mutations detailed in this article, with EGMR and MDL named inventors on these applications. Specifically, these filed patents relate to genetic testing applications of mutations impacting the <i>DOCK8</i> (768802), <i>IL4R</i> (768803), <i>KIAA0556</i> (768804), <i>ITGAL</i> (777216) <i>LRCH4</i> (768805), and <i>RBM34</i> (768806) genes. All other authors declare that they have no competing interests.